Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Management
Corporate Directory
Products
DAYBUE™ (trofinetide)
Pipeline
Pipeline
Trofinetide
Rett Syndrome
Fragile X Syndrome
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Prader-Willi Syndrome
Science
Science Behind Neuren's Products
Scientific Presentations
Publications
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
Aug 30, 2012
Half Yearly Report and Accounts
Aug 09, 2012
Neuren appoints Joe Horrigan VP Clinical and Medical Affairs
Aug 07, 2012
NNZ2566 Rationale in ASDs
Jul 31, 2012
Appendix 4C - quarterly
Jul 06, 2012
Neuren awarded Rett Syndrome trial grant
Jun 08, 2012
Final Director's Interest Notice
Jun 08, 2012
Initial Director's Interest Notice
May 31, 2012
Results of Meeting
May 31, 2012
CEO's address to AGM
May 29, 2012
Neuren announces cancer xenograft testing results
Previous
1
2
3
4
Next